PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
204.50
Positive P/E while Biotechnology median is negative at -4.32. Peter Lynch would investigate competitive advantages in a distressed Biotechnology.
No Data
No Data available this quarter, please select a different quarter.
-214.06
Negative equity while Biotechnology median P/B is 1.50. Seth Klarman would investigate balance sheet restructuring potential.
1843.78
Positive FCF while Biotechnology median shows negative FCF. Peter Lynch would examine cash flow generation advantage.
1843.78
Positive operating cash flow while Biotechnology median is negative. Peter Lynch would examine operational advantage.
-214.06
Negative fair value while Biotechnology median is 1.55. Seth Klarman would investigate valuation model issues.
0.12%
Positive earnings while Biotechnology median shows losses. Peter Lynch would examine earnings quality advantage.
0.05%
Positive FCF while Biotechnology median shows negative FCF. Peter Lynch would examine cash generation advantage.